Clinical Research Unit 216


Characterization of the Oncogenic

Signaling Network in Multiple Myeloma:

Development of Targeted Therapies

funded by DFG

The underlying hypothesis of this Clinical Research Unit is the assumption that in multiple myeloma (MM) the malignant phenotype results from deregulation not of a single but of a number of signaling pathways, and that these pathways collectively constitute an oncogenic signaling network. Consequently, we assume that targeting of various signaling nodes rather than any particular protein or pathway is required to establish effective molecular therapies against this disease – a concept now known as multi-targeted therapy.